Literature DB >> 23243003

Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups.

Rika Kihara1, Tomoyuki Watanabe, Takahiro Yano, Naokuni Uike, Seiichi Okamura, Fumio Kawano, Shuichi Hanada, Kazutaka Sunami, Nobumasa Inoue, Morio Sawamura, Shin-Ichiro Yoshida, Takeshi Shimomura, Kiyoshi Kitano, Yuki Kojima, Keizo Horibe, Hirokazu Nagai.   

Abstract

Mature T cell lymphoma has been noted for poor prognosis when compared with B cell lymphoma, even in the pre-rituximab era. To confirm this difference, a retrospective cohort study was conducted. One hundred-and nineteen patients with mature T cell lymphoma and 568 patients with diffuse large B cell lymphoma (DLBCL) who did not receive rituximab as first induction were studied. Overall survival (OS) was worse for patients with international prognostic index (IPI) scores indicating low-risk mature T cell lymphoma than for those with DLBCL (3-year OS 87 % vs. 58 %, P = 0.001), but not in other risk groups. Prognosis of mature T cell lymphoma was significantly poorer in the IPI low-risk group, as compared with DLBCL.

Entities:  

Mesh：

Year:  2012        PMID： 23243003     DOI： 10.1007/s12185-012-1243-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  7 in total

1.  Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.

Authors:  Dennis D Weisenburger; Kerry J Savage; Nancy Lee Harris; Randy D Gascoyne; Elaine S Jaffe; Kenneth A MacLennan; Thomas Rüdiger; Stefano Pileri; Shigeo Nakamura; Bharat Nathwani; Elias Campo; Francoise Berger; Bertrand Coiffier; Won-Seog Kim; Harald Holte; Massimo Federico; Wing Y Au; Kensei Tobinai; James O Armitage; Julie M Vose
Journal:  Blood       Date:  2011-01-26       Impact factor: 22.113

2.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

Authors: 
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

3.  Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.

Authors:  Hirokazu Nagai; Takahiro Yano; Tomoyuki Watanabe; Naokuni Uike; Seiichi Okamura; Shuichi Hanada; Fumio Kawano; Kazutaka Sunami; Nobumasa Inoue; Morio Sawamura; Tetsuo Nishiura; Tomomitsu Hotta; Keizo Horibe
Journal:  Br J Haematol       Date:  2008-10-20       Impact factor: 6.998

4.  Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index.

Authors:  Chor-Sang Chim; Shing-Yan Ma; Wing-Yan Au; Carolyn Choy; Albert K W Lie; Raymond Liang; Chun-Chung Yau; Yok-Lam Kwong
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

5.  Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

Authors:  Nathalie Mourad; Nicolas Mounier; Josette Brière; Emmanuel Raffoux; Alain Delmer; Alfred Feller; Chris J L M Meijer; Jean-François Emile; Réda Bouabdallah; André Bosly; Jacques Diebold; Corinne Haioun; Bertrand Coiffier; Christian Gisselbrecht; Philippe Gaulard
Journal:  Blood       Date:  2008-02-21       Impact factor: 22.113

6.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).

Authors:  C Gisselbrecht; P Gaulard; E Lepage; B Coiffier; J Brière; C Haioun; D Cazals-Hatem; A Bosly; L Xerri; H Tilly; F Berger; R Bouhabdallah; J Diebold
Journal:  Blood       Date:  1998-07-01       Impact factor: 22.113
  7 in total
  3 in total

1.  Low Expression of CD5 and CD6 Is Associated with Poor Overall Survival for Patients with T-Cell Malignancies.

Authors:  Songnan Sui; Zhiyan Li; Jiaxiong Tan; Liang Wang; Gengxin Luo; Chengwu Zeng; Oscar Junhong Luo; Cunte Chen; Yangqiu Li
Journal:  J Oncol       Date:  2022-08-09       Impact factor: 4.501

2.  Angioimmunoblastic T-cell Lymphoma Presenting as a Methotrexate-associated Lymphoproliferative Disorder with Extreme Peripheral Blood Plasmacytosis.

Authors:  Hiroyuki Murakami; Masanori Makita; Tatsunori Ishikawa; Takanori Yoshioka; Keina Nagakita; Yoko Shinno; Tadashi Yoshino; Yoshinobu Maeda; Kazutaka Sunami
Journal:  Intern Med       Date:  2022-02-08       Impact factor: 1.282

3.  Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis.

Authors:  Hisao Nagoshi; Junya Kuroda; Tsutomu Kobayashi; Saori Maegawa; Yoshiaki Chinen; Miki Kiyota; Ryuko Nakayama; Shinsuke Mizutani; Yuji Shimura; Mio Yamamoto-Sugitani; Yosuke Matsumoto; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2013-08-15       Impact factor: 2.319
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.